Señales en vivo de NYKD.OL | Maximiza tus Ganancias con Getagraph.com

COMPRAR 5087 min ago

@ Kr.14.60

Emitido: 16 may 2024 @ 09:39

Retorno: 0.48%

Señal anterior: may 16 - 06:29

Señal anterior: Vender

Retorno: -0.48 %

Live Chart Being Loaded With Signals

Commentary (16 may 2024 @ 10:25):

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases...

Stats
Volumen de hoy	459 602
Volumen promedio	1.00M
Capitalización de mercado	4.79B
EPS	Kr.-0.520 ( 2024-05-16 )
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	-11.28
ATR14	Kr.0.430 (2.93%)

Volumen Correlación

Largo: 0.00 (neutral)

Corto: 0.00 (neutral)

Signal:(0) Neutral

Nykode Therapeutics AS Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nykode Therapeutics AS Correlación - Moneda/Commodity

0.00
( neutral )

Financial Reports:

No articles found.

Nykode Therapeutics AS Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.